Review of IL-17 inhibitors for psoriasis

Amin, Mina; Darji, Kavita; No, Daniel J.; Bhutani, Tina; Wu, Jashin J.

doi:10.1080/09546634.2017.1395796

Cited by 20 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preclinical studies have provided promising results in murine models of neutrophilic airway diseases by using IL-17A-or IL-17RA-neutralizing antibodies, indicating that IL-17A signaling inhibition could be a novel therapeutic approach for treatment of these steroid-resistant diseases (3, 6-10). Neutralizing monoclonal antibodies (mAbs) (against IL-17A and IL-17RA) have been developed as candidate drugs targeting IL-17A-dependent pathogenesis (39)(40)(41)(42). However, given the considerable cost of antibody production and limited administration (only through the i.v.…”

Section: Discussionmentioning

confidence: 99%

Targeting IL-17A/glucocorticoid synergy to CSF3 expression in neutrophilic airway diseases

Ouyang¹,

Liu²,

Xiao³

et al. 2020

JCI Insight

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Targeting IL-17A/glucocorticoid synergy to CSF3 expression in neutrophilic airway diseases

Ouyang¹,

Liu²,

Xiao³

et al. 2020

JCI Insight

View full text Add to dashboard Cite

“…The changes in skin immunopathology seen herein are consistent with the well-described ability of the gut microbiome to influence immunity in the skin via the so-called gut-skin-axis (158). A role for IL-17 in psoriasis has been established (159) and several studies in humans have also found an association between gut microbiota and Th17 responses (160, 161). Promotion of systemic Th17/IL-17 responses by acetate was also reported in another infectious disease setting where mice were infected orally with the gram-negative enteric bacteria Citrobacter rodentium (19).…”

Section: Discussionmentioning

confidence: 99%

Exacerbation of Chikungunya Virus Rheumatic Immunopathology by a High Fiber Diet and Butyrate

et al. 2019

View full text Add to dashboard Cite

Chikungunya virus (CHIKV) is a mosquito transmitted alphavirus associated with a robust systemic infection and an acute inflammatory rheumatic disease. A high fiber diet has been widely promoted for its ability to ameliorate inflammatory diseases. Fiber is fermented in the gut into short chain fatty acids such as acetate, propionate, and butyrate, which enter the circulation providing systemic anti-inflammatory activities. Herein we show that mice fed a high fiber diet show a clear exacerbation of CHIKV arthropathy, with increased edema and neutrophil infiltrates. RNA-Seq analyses illustrated that a high fiber diet, in this setting, promoted a range of pro-neutrophil responses including Th17/IL-17. Gene Set Enrichment Analyses demonstrated significant similarities with mouse models of inflammatory psoriasis and significant depression of macrophage resolution phase signatures in the CHIKV arthritic lesions from mice fed a high fiber diet. Supplementation of the drinking water with butyrate also increased edema after CHIKV infection. However, the mechanisms involved were different, with modulation of AP-1 and NF-κB responses identified, potentially implicating deoptimization of endothelial barrier repair. Thus, neither fiber nor short chain fatty acids provided benefits in this acute infectious disease setting, which is characterized by widespread viral cytopathic effects and a need for tissue repair.

show abstract

“…Comparative reviews on anti-IL-17 drugs reported that all three drugs were well-tolerated in patients with moderate-to-severe psoriasis; however, adverse effects, such as respiratory tract infections, were reported more frequently for ixekizumab, and it was withdrawn in some cases due to its toxicity [204,205]. A meta-analysis on efficacy of anti-IL-17 drugs on rheumatoid arthritis showed that secukinumab and ixekizumab were more effective compared to placebo; however, an increased risk of infection in the test group has also been reported [206].…”

Section: Th17/il-17 As Targets In the Management Of Imids And Its mentioning

confidence: 99%

Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases

Bunte

Beikler

2019

IJMS

341

290

View full text Add to dashboard Cite

Innate immunity represents the semi-specific first line of defense and provides the initial host response to tissue injury, trauma, and pathogens. Innate immunity activates the adaptive immunity, and both act highly regulated together to establish and maintain tissue homeostasis. Any dysregulation of this interaction can result in chronic inflammation and autoimmunity and is thought to be a major underlying cause in the initiation and progression of highly prevalent immune-mediated inflammatory diseases (IMIDs) such as psoriasis, rheumatoid arthritis, inflammatory bowel diseases among others, and periodontitis. Th1 and Th2 cells of the adaptive immune system are the major players in the pathogenesis of IMIDs. In addition, Th17 cells, their key cytokine IL-17, and IL-23 seem to play pivotal roles. This review aims to provide an overview of the current knowledge about the differentiation of Th17 cells and the role of the IL-17/IL-23 axis in the pathogenesis of IMIDs. Moreover, it aims to review the association of these IMIDs with periodontitis and briefly discusses the therapeutic potential of agents that modulate the IL-17/IL-23 axis.

show abstract

Review of IL-17 inhibitors for psoriasis

Cited by 20 publications

References 29 publications

Targeting IL-17A/glucocorticoid synergy to CSF3 expression in neutrophilic airway diseases

Targeting IL-17A/glucocorticoid synergy to CSF3 expression in neutrophilic airway diseases

Exacerbation of Chikungunya Virus Rheumatic Immunopathology by a High Fiber Diet and Butyrate

Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases

Contact Info

Product

Resources

About